{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:07:48Z","timestamp":1791486468415,"version":"4.3.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Omega-3 polyunsaturated fatty acids lower triglycerides and modulate inflammation, thrombosis, and endothelial function, providing a rationale for their use in cardiovascular prevention. This review examines the influence of formulation, dose, and patient selection on clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A targeted PubMed search through 31 May 2026 informed the selection of randomized trials and relevant mechanistic and observational studies, complemented by guideline and regulatory documents and selected publications added during revision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Low-dose mixed eicosapentaenoic acid (EPA)\/docosahexaenoic acid (DHA) formulations were generally neutral in contemporary prevention trials. JELIS reported fewer major coronary events with EPA 1.8\u00a0g\/day (2.8% vs. 3.5%; hazard ratio 0.81). In REDUCE-IT, icosapent ethyl 4\u00a0g\/day reduced major ischemic events (17.2% vs. 22.0%; hazard ratio 0.75), whereas STRENGTH found no benefit with 4\u00a0g\/day EPA\/DHA (12.0% vs. 12.2%; hazard ratio 0.99). Differences in biological exposure, placebo choice, and pharmacological properties may contribute to these findings, although their relative importance remains debated. Evidence for stroke, heart failure, and peripheral artery disease varies by population and endpoint, while higher-dose therapy requires attention to atrial fibrillation and bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence supports prescription icosapent ethyl in selected statin-treated patients with persistent hypertriglyceridemia, with treatment guided by cardiovascular risk, formulation, and dose rather than considering omega-3 preparations as an interchangeable class.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10557-026-07974-4","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:49:11Z","timestamp":1791438551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Omega-3 Fatty Acids in the Management of Cardiovascular Disease Prevention"],"prefix":"10.1007","author":[{"given":"Simone","family":"Finocchiaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Cutore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Bordonaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Cusmano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Nastasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Nasisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"7974_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s43094-024-00667-5","volume":"10","author":"PG Patted","year":"2024","unstructured":"Patted PG, Masareddy RS, Patil AS, Kanabargi RR, Bhat CT. Omega-3 fatty acids: a comprehensive scientific review of their sources, functions and health benefits. Futur J Pharm Sci. 2024;10:94. https:\/\/doi.org\/10.1186\/s43094-024-00667-5.","journal-title":"Futur J Pharm Sci"},{"issue":"6","key":"7974_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.4065\/75.6.607","volume":"75","author":"JH O\u2019Keefe","year":"2000","unstructured":"O\u2019Keefe JH, Harris WS. From Inuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc. 2000;75(6):607\u201314. https:\/\/doi.org\/10.4065\/75.6.607.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"7974_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.cjca.2014.04.007","volume":"30","author":"JG Fodor","year":"2014","unstructured":"Fodor JG, Helis E, Yazdekhasti N, Vohnout B. Fishing for the origins of the Eskimos and heart disease story: facts or wishful thinking? Can J Cardiol. 2014;30(8):864\u20138. https:\/\/doi.org\/10.1016\/j.cjca.2014.04.007.","journal-title":"Can J Cardiol"},{"issue":"12","key":"7974_CR4","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s11745-999-0481-6","volume":"34","author":"M Hashimoto","year":"1999","unstructured":"Hashimoto M, Hossain S, Yamasaki H, Yazawa K, Masumura S. Effects of eicosapentaenoic acid and docosahexaenoic acid on plasma membrane fluidity of aortic endothelial cells. Lipids. 1999;34(12):1297\u2013304. https:\/\/doi.org\/10.1007\/s11745-999-0481-6.","journal-title":"Lipids"},{"issue":"2","key":"7974_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jnutbio.2011.07.001","volume":"23","author":"SR Shaikh","year":"2012","unstructured":"Shaikh SR. Biophysical and biochemical mechanisms by which dietary N-3 polyunsaturated fatty acids from fish oil disrupt membrane lipid rafts. J Nutr Biochem. 2012;23(2):101\u20135. https:\/\/doi.org\/10.1016\/j.jnutbio.2011.07.001.","journal-title":"J Nutr Biochem"},{"issue":"8666","key":"7974_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/s0140-6736(89)90828-3","volume":"2","author":"ML Burr","year":"1989","unstructured":"Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2(8666):757\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(89)90828-3.","journal-title":"Lancet"},{"issue":"9177","key":"7974_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","volume":"354","author":"GISSI-Prevenzione Investigators","year":"1999","unstructured":"GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354(9177):447\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(99)07072-5.","journal-title":"Lancet"},{"issue":"12","key":"7974_CR8","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1161\/ATVBAHA.110.215848","volume":"30","author":"CL Chang","year":"2010","unstructured":"Chang CL, Seo T, Du CB, Accili D, Deckelbaum RJ. n-3 Fatty acids decrease arterial low-density lipoprotein cholesterol delivery and lipoprotein lipase levels in insulin-resistant mice. Arterioscler Thromb Vasc Biol. 2010;30(12):2510\u20137. https:\/\/doi.org\/10.1161\/ATVBAHA.110.215848.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"7974_CR9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3945\/ajcn.2009.27680","volume":"90","author":"M Bouwens","year":"2009","unstructured":"Bouwens M, van de Rest O, Dellschaft N, et al. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr. 2009;90(2):415\u201324. https:\/\/doi.org\/10.3945\/ajcn.2009.27680.","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"7974_CR10","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1194\/jlr.M022657","volume":"53","author":"PJ Gillies","year":"2012","unstructured":"Gillies PJ, Bhatia SK, Belcher LA, Hannon DB, Thompson JT, Vanden Heuvel JP. Regulation of inflammatory and lipid metabolism genes by eicosapentaenoic acid-rich oil. J Lipid Res. 2012;53(8):1679\u201389. https:\/\/doi.org\/10.1194\/jlr.M022657.","journal-title":"J Lipid Res"},{"issue":"7","key":"7974_CR11","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1172\/JCI97943","volume":"128","author":"CN Serhan","year":"2018","unstructured":"Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018;128(7):2657\u201369. https:\/\/doi.org\/10.1172\/JCI97943.","journal-title":"J Clin Invest"},{"issue":"21","key":"7974_CR12","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","volume":"122","author":"B Rauch","year":"2010","unstructured":"Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.948562.","journal-title":"Circulation"},{"key":"7974_CR13","doi-asserted-by":"publisher","first-page":"c6273","DOI":"10.1136\/bmj.c6273","volume":"341","author":"P Galan","year":"2010","unstructured":"Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273. https:\/\/doi.org\/10.1136\/bmj.c6273.","journal-title":"BMJ"},{"issue":"1","key":"7974_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1811403","volume":"380","author":"JE Manson","year":"2019","unstructured":"Manson JE, Cook NR, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2019;380(1):23\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1811403.","journal-title":"N Engl J Med"},{"issue":"16","key":"7974_CR15","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018;379(16):1540\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1804989.","journal-title":"N Engl J Med"},{"issue":"1","key":"7974_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"issue":"5","key":"7974_CR17","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.3390\/ijms22052394","volume":"22","author":"J Golanski","year":"2021","unstructured":"Golanski J, Szymanska P, Rozalski M. Effects of Omega-3 Polyunsaturated Fatty Acids and Their Metabolites on Haemostasis-Current Perspectives in Cardiovascular Disease. Int J Mol Sci. 2021;22(5):2394. https:\/\/doi.org\/10.3390\/ijms22052394.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7974_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11010-021-04260-9","volume":"477","author":"R Mallick","year":"2022","unstructured":"Mallick R, Duttaroy AK. Modulation of endothelium function by fatty acids. Mol Cell Biochem. 2022;477(1):15\u201338. https:\/\/doi.org\/10.1007\/s11010-021-04260-9.","journal-title":"Mol Cell Biochem"},{"key":"7974_CR19","doi-asserted-by":"publisher","first-page":"102337","DOI":"10.1016\/j.plefa.2021.102337","volume":"173","author":"SCR Sherratt","year":"2021","unstructured":"Sherratt SCR, Dawoud H, Bhatt DL, Malinski T, Mason RP. Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability. Prostaglandins Leukot Essent Fat Acids. 2021;173:102337. https:\/\/doi.org\/10.1016\/j.plefa.2021.102337.","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"issue":"47","key":"7974_CR20","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehab551.","journal-title":"Eur Heart J"},{"issue":"1","key":"7974_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/FJC.0000000000000379","volume":"68","author":"RP Mason","year":"2016","unstructured":"Mason RP, Sherratt SC, Jacob RF. Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents. J Cardiovasc Pharmacol. 2016;68(1):33\u201340. https:\/\/doi.org\/10.1097\/FJC.0000000000000379.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"12","key":"7974_CR22","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","volume":"140","author":"AC Skulas-Ray","year":"2019","unstructured":"Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation. 2019;140(12):e673\u201391. https:\/\/doi.org\/10.1161\/CIR.0000000000000709.","journal-title":"Circulation"},{"issue":"8","key":"7974_CR23","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s11745-005-1443-8","volume":"40","author":"W Guo","year":"2005","unstructured":"Guo W, Xie W, Lei T, Hamilton JA. Eicosapentaenoic acid, but not oleic acid, stimulates beta-oxidation in adipocytes. Lipids. 2005;40(8):815\u201321. https:\/\/doi.org\/10.1007\/s11745-005-1443-8.","journal-title":"Lipids"},{"issue":"20","key":"7974_CR24","doi-asserted-by":"publisher","first-page":"7628","DOI":"10.3390\/ijms21207628","volume":"21","author":"N Tu\u0142owiecka","year":"2020","unstructured":"Tu\u0142owiecka N, Kotl\u0119ga D, Prowans P, Szczuko M. The Role of Resolvins: EPA and DHA Derivatives Can Be Useful in the Prevention and Treatment of Ischemic Stroke. Int J Mol Sci. 2020;21(20):7628. https:\/\/doi.org\/10.3390\/ijms21207628.","journal-title":"Int J Mol Sci"},{"key":"7974_CR25","doi-asserted-by":"publisher","unstructured":"Mohammady M, Brown T, Radmehr M, Shamsoddin E, Janani L. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev. 2024;10CD003833. https:\/\/doi.org\/10.1002\/14651858.CD003833.pub5.","DOI":"10.1002\/14651858.CD003833.pub5"},{"issue":"40","key":"7974_CR26","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","volume":"41","author":"MJ Budoff","year":"2020","unstructured":"Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925\u201332. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa652.","journal-title":"Eur Heart J"},{"issue":"6","key":"7974_CR27","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1161\/01.cir.99.6.779","volume":"99","author":"M de Lorgeril","year":"1999","unstructured":"de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779\u201385. https:\/\/doi.org\/10.1161\/01.cir.99.6.779.","journal-title":"Circulation"},{"issue":"9567","key":"7974_CR28","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"M Yokoyama","year":"2007","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(07)60527-3.","journal-title":"Lancet"},{"issue":"4","key":"7974_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1203859","volume":"367","author":"ORIGIN Trial Investigators","year":"2012","unstructured":"Trial Investigators ORIGIN, Bosch J, Gerstein HC, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1203859.","journal-title":"N Engl J Med"},{"issue":"19","key":"7974_CR30","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1205409","volume":"368","author":"MC Roncaglioni","year":"2013","unstructured":"Risk and Prevention Study Collaborative Group, Roncaglioni MC, Tombesi M, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1205409.","journal-title":"N Engl J Med"},{"issue":"22","key":"7974_CR31","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268\u201380. https:\/\/doi.org\/10.1001\/jama.2020.22258.","journal-title":"JAMA"},{"issue":"6","key":"7974_CR32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.121.054539","volume":"144","author":"JA Bostrom","year":"2021","unstructured":"Bostrom JA, Beckman JA, Berger JS. Summoning STRENGTH to Question the Placebo in REDUCE-IT. Circulation. 2021;144(6):407\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054539.","journal-title":"Circulation"},{"issue":"8","key":"7974_CR33","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1001\/jamacardio.2021.1157","volume":"6","author":"SE Nissen","year":"2021","unstructured":"Nissen SE, Lincoff AM, Wolski K, et al. Association Between Achieved \u03c9-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. JAMA Cardiol. 2021;6(8):910\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2021.1157.","journal-title":"JAMA Cardiol"},{"issue":"Suppl J","key":"7974_CR34","doi-asserted-by":"publisher","first-page":"J34","DOI":"10.1093\/eurheartj\/suaa117","volume":"22","author":"B Olshansky","year":"2020","unstructured":"Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl. 2020;22(Suppl J):J34\u201348. https:\/\/doi.org\/10.1093\/eurheartj\/suaa117.","journal-title":"Eur Heart J Suppl"},{"issue":"5","key":"7974_CR35","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","volume":"146","author":"PM Ridker","year":"2022","unstructured":"Ridker PM, Rifai N, MacFadyen J, et al. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1\u03b2, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation. 2022;146(5):372\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059410.","journal-title":"Circulation"},{"issue":"21","key":"7974_CR36","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","volume":"363","author":"D Kromhout","year":"2010","unstructured":"Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1003603.","journal-title":"N Engl J Med"},{"issue":"6","key":"7974_CR37","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","volume":"143","author":"AA Kalstad","year":"2021","unstructured":"Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial. Circulation. 2021;143(6):528\u201339. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052209.","journal-title":"Circulation"},{"issue":"6","key":"7974_CR38","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1161\/CIRCULATIONAHA.123.065520","volume":"150","author":"K Miyauchi","year":"2024","unstructured":"Miyauchi K, Iwata H, Nishizaki Y, et al. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation. 2024;150(6):425\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065520.","journal-title":"Circulation"},{"issue":"1","key":"7974_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1161\/STROKEAHA.123.044281","volume":"55","author":"JH O\u2019Keefe","year":"2024","unstructured":"O\u2019Keefe JH, Tintle NL, Harris WS, et al. Omega-3 Blood Levels and Stroke Risk: A Pooled and Harmonized Analysis of 183 291 Participants From 29 Prospective Studies. Stroke. 2024;55(1):50\u20138. https:\/\/doi.org\/10.1161\/STROKEAHA.123.044281.","journal-title":"Stroke"},{"issue":"9645","key":"7974_CR40","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","volume":"372","author":"L Tavazzi","year":"2008","unstructured":"Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(08)61239-8.","journal-title":"Lancet"},{"issue":"6","key":"7974_CR41","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1111\/dom.13674","volume":"21","author":"GR Dagenais","year":"2019","unstructured":"Dagenais GR, Jung H, Bogaty P, Bosch J, Yusuf S, Gerstein HC. Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial. Diabetes Obes Metab. 2019;21(6):1502\u20135. https:\/\/doi.org\/10.1111\/dom.13674.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"7974_CR42","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1056\/NEJMoa2513032","volume":"394","author":"CE Lok","year":"2026","unstructured":"Lok CE, Farkouh M, Hemmelgarn BR, et al. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. N Engl J Med. 2026;394(2):128\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2513032.","journal-title":"N Engl J Med"},{"key":"7974_CR43","doi-asserted-by":"publisher","first-page":"100997","DOI":"10.1016\/j.eclinm.2021.100997","volume":"38","author":"SU Khan","year":"2021","unstructured":"Khan SU, Lone AN, Khan MS, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClinicalMedicine. 2021;38:100997. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100997.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"7974_CR44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ypmed.2004.02.030","volume":"39","author":"WS Harris","year":"2004","unstructured":"Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004;39(1):212\u201320. https:\/\/doi.org\/10.1016\/j.ypmed.2004.02.030.","journal-title":"Prev Med"},{"issue":"8","key":"7974_CR45","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/ehjcvp\/pvaf058","volume":"11","author":"S Finocchiaro","year":"2025","unstructured":"Finocchiaro S, Mazzone PM, Ammirabile N, et al. Anti-inflammatory pharmacotherapy in patients with cardiovascular disease. Eur Heart J Cardiovasc Pharmacother. 2025;11(8):712\u201328. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf058.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"25","key":"7974_CR46","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.121.055654","volume":"144","author":"B Gencer","year":"2021","unstructured":"Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of Long-Term Marine \u0277-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation. 2021;144(25):1981\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.055654.","journal-title":"Circulation"},{"issue":"2","key":"7974_CR47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.12997\/jla.2024.13.2.89","volume":"13","author":"B Dwiputra","year":"2024","unstructured":"Dwiputra B, Ambari AM, Desandri DR, et al. The Effect of Omega-3 Supplementation on Heart Failure Outcome: A Meta-Analysis of Randomized Clinical Trial. J Lipid Atheroscler. 2024;13(2):89\u201396. https:\/\/doi.org\/10.12997\/jla.2024.13.2.89.","journal-title":"J Lipid Atheroscler"},{"issue":"22","key":"7974_CR48","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","volume":"144","author":"A Majithia","year":"2021","unstructured":"Majithia A, Bhatt DL, Friedman AN, et al. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation. 2021;144(22):1750\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.055560.","journal-title":"Circulation"},{"issue":"12","key":"7974_CR49","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2459\/JCM.0000000000001812","volume":"26","author":"S Finocchiaro","year":"2025","unstructured":"Finocchiaro S, Mauro MS, Laudani C, et al. Long-term outcomes of percutaneous coronary intervention for recurrent events in patients undergoing target-vessel vs. nontarget-vessel revascularization. J Cardiovasc Med (Hagerstown). 2025;26(12):714\u201323. https:\/\/doi.org\/10.2459\/JCM.0000000000001812.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"4","key":"7974_CR50","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s10557-026-07855-w","volume":"40","author":"L Bonanni","year":"2026","unstructured":"Bonanni L, Cutolo A, Ferri N. The 2025 ESC\/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications. Cardiovasc Drugs Ther. 2026;40(4):1629\u201335. https:\/\/doi.org\/10.1007\/s10557-026-07855-w.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"7974_CR51","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s10557-024-07587-9","volume":"39","author":"C Chen","year":"2025","unstructured":"Chen C, Wei FF, Dong Y, Liu C. Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review. Cardiovasc Drugs Ther. 2025;39(6):1465\u201380. https:\/\/doi.org\/10.1007\/s10557-024-07587-9.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"7974_CR52","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s10557-023-07519-z","volume":"39","author":"H Sabbour","year":"2025","unstructured":"Sabbour H, Bhatt DL, Elhenawi Y, et al. A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids. Cardiovasc Drugs Ther. 2025;39(5):1135\u201351. https:\/\/doi.org\/10.1007\/s10557-023-07519-z.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"19","key":"7974_CR53","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, et al. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. N Engl J Med. 2024;390(19):1770\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2402309.","journal-title":"N Engl J Med"},{"issue":"5","key":"7974_CR54","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa2512761","volume":"394","author":"NA Marston","year":"2026","unstructured":"Marston NA, Bergmark BA, Alexander VJ, et al. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. N Engl J Med. 2026;394(5):429\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2512761.","journal-title":"N Engl J Med"},{"issue":"42","key":"7974_CR55","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, van Roeters JE, et al. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359\u201378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","journal-title":"Eur Heart J"},{"issue":"17","key":"7974_CR56","doi-asserted-by":"publisher","first-page":"e1154","DOI":"10.1161\/CIR.0000000000001423","volume":"153","author":"RS Blumenthal","year":"2026","unstructured":"Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154\u2013276. https:\/\/doi.org\/10.1161\/CIR.0000000000001423.","journal-title":"Circulation"},{"key":"7974_CR57","unstructured":"Amarin, Pharma. Inc. Vascepa (icosapent ethyl) capsules, prescribing information. DailyMed. Revised March 2026. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=9c1a2828-1583-4414-ab22-a60480e8e508. Accessed 9 Sep 2026."},{"key":"7974_CR58","unstructured":"European Medicines Agency. Vazkepa: European public assessment report and product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vazkepa. Accessed 9 Sep 2026."},{"issue":"6","key":"7974_CR59","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/jsfa.6816","volume":"95","author":"AC Kleiner","year":"2015","unstructured":"Kleiner AC, Cladis DP, Santerre CR. A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States. J Sci Food Agric. 2015;95(6):1260\u20137. https:\/\/doi.org\/10.1002\/jsfa.6816.","journal-title":"J Sci Food Agric"},{"issue":"2","key":"7974_CR60","doi-asserted-by":"publisher","first-page":"e2148172","DOI":"10.1001\/jamanetworkopen.2021.48172","volume":"5","author":"WS Weintraub","year":"2022","unstructured":"Weintraub WS, Bhatt DL, Zhang Z, et al. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open. 2022;5(2):e2148172. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.48172.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"7974_CR61","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2021.1489","volume":"325","author":"CM Albert","year":"2021","unstructured":"Albert CM, Cook NR, Pester J, et al. Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial. JAMA. 2021;325(11):1061\u201373. https:\/\/doi.org\/10.1001\/jama.2021.1489.","journal-title":"JAMA"},{"key":"7974_CR62","doi-asserted-by":"publisher","DOI":"10.1055\/a-2862-6563","author":"MS Mauro","year":"2026","unstructured":"Mauro MS, Finocchiaro S, Calderone D, Laudani C, Greco A, Capodanno D. Bleeding and Thrombotic Trade-off in Dual-Risk Patients Undergoing Percutaneous Coronary Intervention. Thromb Haemost. 2026. https:\/\/doi.org\/10.1055\/a-2862-6563.","journal-title":"Thromb Haemost"},{"issue":"11","key":"7974_CR63","doi-asserted-by":"publisher","first-page":"e004584","DOI":"10.1161\/CIRCOUTCOMES.118.004584","volume":"11","author":"E Akintoye","year":"2018","unstructured":"Akintoye E, Sethi P, Harris WS, et al. Fish Oil and Perioperative Bleeding. Circ Cardiovasc Qual Outcomes. 2018;11(11):e004584. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.118.004584.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"7974_CR64","doi-asserted-by":"publisher","unstructured":"Finocchiaro S, Mauro MS, Bordonaro C, et al. Comparison of the 2025 ESC\/EAS and 2026 ACC\/AHA guidelines for dyslipidaemia management. Eur J Prev Cardiol. 2026;zwag413. https:\/\/doi.org\/10.1093\/eurjpc\/zwag413.","DOI":"10.1093\/eurjpc\/zwag413"},{"issue":"21","key":"7974_CR65","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/01.cir.0000038493.65177.94","volume":"106","author":"PM Kris-Etherton","year":"2002","unstructured":"Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747\u201357. https:\/\/doi.org\/10.1161\/01.cir.0000038493.65177.94.","journal-title":"Circulation"},{"key":"7974_CR66","unstructured":"US Food and Drug Administration. Vascepa (icosapent ethyl) prescribing information. Revised. December 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202057s035lbl.pdf. Accessed 9 Sep 2026."},{"key":"7974_CR67","unstructured":"European Medicines Agency. EMA confirms omega-3 fatty acid medicines are not effective in preventing further heart problems after a heart attack. 2019. https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack. Accessed 9 Sep 2026."},{"key":"7974_CR68","unstructured":"ClinicalTrials.gov. Study records NCT01653678, NCT06279793, and NCT06995586. https:\/\/clinicaltrials.gov. Accessed 18 Sep 2026."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07974-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:03:51Z","timestamp":1791482631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07974-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":68,"alternative-id":["7974"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07974-4","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"13 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ChatGPT (OpenAI) was used during revision to assist with language editing and the identification and formatting of references. Responsibility for the content, interpretation, and accuracy of the manuscript rests with the authors.","order":1,"name":"Ethics","label":"Use of Large Language Models","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}